Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6223870 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL10131262 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL18535303 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL6841285 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL13191782 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL12374614 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL24672314 | 0.85 | CA2 (0.35) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL8815319 | 0.85 | CA2 (0.35) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL13191781 | 0.85 | CA2 (0.35) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL24687709 | 0.83 | CA2 (0.35) | CA2CA1CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331068-B2 | Compositions and methods for inhibiting CD73 | PELOTON THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-3810109-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING CD73 | PELOTON THERAPEUTICS INC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-12054512-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-08-06 | — | — | US | disclosed |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| CN-110291095-B | Adenosine analogues and their use in regulating circadian clock | 北京生命科学研究所 | 2023-04-18 | — | — | CN | disclosed |
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-03 | — | — | US | disclosed |
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-03 | — | — | US | disclosed |
| EP-3707151-B1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICALS CO (JP) | 2022-01-05 | — | — | EP | disclosed |
| US-20210338706-A1 | ADENOSINE ANALOG AND ITS USE IN REGULATING THE CIRCADIAN CLOCK | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-11-04 | — | — | US | disclosed |
| US-20060264390-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | IONIS PHARMACEUTICALS, INC. | 2006-11-23 | — | — | US | disclosed |
| US-7125855-B2 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK & CO., INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20060205686-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN | 2006-09-14 | — | — | US | disclosed |
| US-7105499-B2 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK & CO., INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20050272676-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN | 2005-12-08 | — | — | US | disclosed |
| US-6777395-B2 | VIRICIDES | MERCK & CO., INC. | 2004-08-17 | — | — | US | disclosed |
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2004-04-08 | — | — | US | disclosed |
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | ISIS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2002-10-10 | — | — | US | disclosed |
| US-6069132-A | PYRIMIDOPHOSOHAZOLE RING SYSTEM OF GIVEN STRUCTURE, THE TRIVALENT PHOSPHORUS OF THE RING SUBSTITUTED WITH VARIOUS GROUPS; NEW CLASS OF PHOSPHORUS CONTAINING HETEROCYCLES WITH APPLICATION IN MEDICAL, AGRICULTURAL AND INDUSTRIAL USE | ARONEX PHARMACEUTICALS, INC. | 2000-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | CA2 4649/4885CA1 4728/4885CA9 4292/4885 |
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | CA2 3019/4885CA1 4845/4885CA9 4183/4885 |
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | RNASE1, RNASEH1, RNASEL | CA2 3466/4885CA1 2420/4885CA9 2062/4885 |
| US-20060264390-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | CA2 4649/4885CA1 4728/4885CA9 4292/4885 |
| US-20050272676-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | CA2 4649/4885CA1 4728/4885CA9 4292/4885 |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | CA2 4649/4885CA1 4728/4885CA9 4292/4885 |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | CA2 3019/4885CA1 4845/4885CA9 4183/4885 |
| US-12331068-B2 | Compositions and methods for inhibiting CD73 | ENTPD5, NT5E, ENTPD1 | CA2 824/4885CA1 1176/4885CA9 787/4885 |
| US-12054512-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | CA2 3019/4885CA1 4845/4885CA9 4183/4885 |
| US-20210338706-A1 | ADENOSINE ANALOG AND ITS USE IN REGULATING THE CIRCADIAN CLOCK | PER2, CRY1, ADORA2A | CA2 3840/4885CA1 2846/4885CA9 4472/4885 |
| US-20060205686-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | CA2 4649/4885CA1 4728/4885CA9 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.